Philips Healthcare has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for its Magnetic Resonance for Calculating Attenuation (MRCAT) pelvis software.
MRCAT pelvis supports radiation therapy (RT) planning based on one MRI exam for cancers in the pelvis, including the bladder, rectum, anus, and cervix, according to the vendor. The software is the latest addition to the firm's MRCAT simulation portfolio; MRCAT was first introduced in 2016 for use in prostate cancer treatment planning.
Philips noted that MRCAT pelvis has also received clearance by Health Canada, as well as the CE Mark for sale in Europe. The software can be utilized on the vendor's wide-bore digital Ingenia MR-RT platform, which includes the Ingenia Elition 3-tesla and Ingenia Ambition 1.5-tesla MR-RT systems.
